SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES ACT OF 1934
Date of Report (Date of earliest event reported): July 18, 2002
HEMACARE CORPORATION
____________________________
(Exact name of registrant as
specified in its chapter)
California
____________________________
(State or other jurisdiction
of incorporation)
0-15223 95-3280412
______________________ _________________________________
Commission File Number (IRS Employer Identification No.)
21101 Oxnard Street, Woodland Hills, California 91367
________________________________________________ __________
(Address of principal executive (Zip Code)
Registrant's telephone number, including area code: (818) 226-1968
______________
2
Item 4. Change in Registrant's Certifying Accountant.
- ------- ---------------------------------------------
On July 18, 2002, HemaCare Corporation (the "Company") in
accordance with actions authorized by the Board of
Directors, and upon recommendation of its audit committee,
has appointed Ernst & Young LLP as the Company's independent
public accountants, replacing Arthur Andersen LLP. The
Company dismissed Arthur Andersen LLP on the same date.
Ernst & Young has notified the Company that is has accepted
the engagement.
The audit reports of Arthur Andersen LLP on the consolidated
financial statements of the Company as of and for the fiscal
years ended December 31, 2001 and 2000 did not contain any
adverse opinion or disclaimer of opinion, nor were they
qualified or modified as to uncertainty, audit scope or
accounting principles.
During the two most recent fiscal years of the Company,
ended December 31, 2001 and 2000 respectively, and the
subsequent interim period to the date hereof, there were no
disagreements between the Company and Arthur Andersen LLP on
any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to Arthur Andersen's
satisfaction, would have caused Arthur Andersen LLP to make
reference to the subject matter of the disagreement in
connection with its reports.
None of the reportable events described under Item 304 (a)
(1) (v) of Regulation S-K occurred within the two most
recent fiscal years of the Company and the subsequent
interim period to the date hereof.
During the two most recent fiscal years of the Company and
the subsequent interim period to the date thereof, the
Company did not consult with Ernst & Young LLP regarding any
of the matters or events set forth in the Item 304 (a) (2)
(i) and (ii) of Regulation S-K.
Pursuant to Item 304T issued by Release No. 33-8070, the
Issuer has not obtained and is not able to obtain a letter
from Arthur Andersen relating to the above change in
auditors.
Item 7. Financial Statements and Exhibits.
- ------- -----------------------------------
Exhibit Number Description of Document
- --------------- ------------------------
None
2
3
Signature
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
Date: July 18, 2002 HEMACARE CORPORATION
-------------
By: /s/ David E. Fractor
----------------------------
David E. Fractor
Chief Financial Officer
3